Moderna company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
A reported phase III win tied to Moderna’s cancer therapy is renewing attention on the company’s messenger RNA (mRNA) approach, even as questions about durability of clinical progress and competitive dynamics remain.
THE APEX TIMES
THE APEX TIMES
A new discussion of an mRNA cancer vaccine partnership between Moderna and Merck highlights the promise, and the remaining uncertainty, around vaccines designed to help the immune system recognize cancer.
THE APEX TIMES
A Yahoo Finance-linked screen pointed to three other American-listed names showing the same chart and momentum setup that helped Moderna rally sharply, while also stressing that none are biotech.
THE APEX TIMES
A dramatic surge in Moderna shares helped push the healthcare sector higher, according to a market report published this week, underscoring how quickly sentiment can swing around a single high-profile biotech name.
THE APEX TIMES
Revere Asset Management’s Don Vandenbord says AI-focused capital that starts in software and platforms could broaden into biotech, with Moderna’s stock becoming one of the familiar places to watch.
THE APEX TIMES
Moderna shares jumped and BioNTech rose as traders revisited the same clinical catalyst across multiple sessions, with options activity suggesting the volatility may not be finished.
THE APEX TIMES
Moderna shares ended the week higher after a session marked by sharp swings, while crypto-related stocks reportedly extended a recent rally in a broader risk-on market tone.
THE APEX TIMES
In a market roundup, Moderna shares ended a volatile week higher, and investors also watched Robinhood and Ross Stores alongside firms tied to crypto’s latest push higher.
THE APEX TIMES
A Yahoo Finance market roundup on Aug. 21 pointed to broad pressure across fixed income, digital assets, and U.S. biotech, with Moderna (MRNA) cited as part of the wider “chaos” theme investors are tracking.
